Brief: Xortx Announces 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Price Deficiency
24/05/2023 12:17
May 24 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX ANNOUNCES 180-DAY EXTENSION TO REGAIN COMPLIANCE
WITH
NASDAQ MINIMUM BID PRICE DEFICIENCY
Source text for Eikon: ID:nGNX7dKdTC
Further company coverage: XRTX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering